NUDT18

Across TCGA pan-cancer cohorts, NUDT18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NUDT18 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NUDT18 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NUDT18 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where NUDT18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.948	0.624	.002	27	view →
UCEC	DFS	Quartile	All	1.000	0.751	.003	14	view →
PDAC	DFS	Tertile	III,IV	0.212	0.747	.010	8	view →
HNSC	OS	Quartile	II,III,IV	0.933	0.721	.013	4	view →
LUAD	OS	Quartile	II,III,IV	0.866	0.368	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NUDT18–CCRCC (DFS)

Open the CCRCC breakdown →